|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2007-4-9
|
|
pubmed:abstractText |
The majority of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) are older than 60 years, yet they are often denied potentially curative high-dose therapy and autologous stem-cell transplantations (ASCT) because of the risk of excessive treatment-related morbidity and mortality. Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites while limiting exposure to normal organs and may be particularly suited for older adults requiring high-dose therapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
10
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1396-402
|
|
pubmed:dateRevised |
2007-12-3
|
|
pubmed:meshHeading |
pubmed-meshheading:17312330-Aged,
pubmed-meshheading:17312330-Antibodies, Monoclonal,
pubmed-meshheading:17312330-Antigens, CD20,
pubmed-meshheading:17312330-Antineoplastic Agents,
pubmed-meshheading:17312330-Chi-Square Distribution,
pubmed-meshheading:17312330-Combined Modality Therapy,
pubmed-meshheading:17312330-Disease Progression,
pubmed-meshheading:17312330-Female,
pubmed-meshheading:17312330-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17312330-Humans,
pubmed-meshheading:17312330-Iodine Radioisotopes,
pubmed-meshheading:17312330-Lymphoma, B-Cell,
pubmed-meshheading:17312330-Male,
pubmed-meshheading:17312330-Middle Aged,
pubmed-meshheading:17312330-Radioimmunotherapy,
pubmed-meshheading:17312330-Radiotherapy Dosage,
pubmed-meshheading:17312330-Survival Analysis,
pubmed-meshheading:17312330-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
|
|
pubmed:affiliation |
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98195, USA. agopal@u.washington.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
